NAFLD score: Non-alcoholic fatty liver disease score.
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highest risk for progressing to end-stage liver disease. Current model consists and validated a scoring system consisting of routinely measured and readily available clinical and laboratory data to separate NAFLD patients with and without advanced fibrosis.
Research authors: Paul Angulo, Jason M. Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C. Farrell, Felicity Enders, Sushma Saksena, Alastair D. Burt, John P. Bida, Keith Lindor, Schuyler O. Sanderson, Marco Lenzi, Leon A. Adams, James Kench, Terry M Therneau, Christopher P. day
General details Custom formula Study characteristics Files & References Validations
★★★★
Model author
Model ID
966
Version
1.6
Revision date
2017-10-05
Medical specialty
MeSH terms
  • Fibrosis
  • Liver Fibrosis
  • Liver Disease
  • Liver Disease
  • Fibrosis
  • Non alcoholic Fatty Liver Disease
  • Model Type
    Linear model (Calculation)
    Status
    public
    Rating
    Share
    Formula
    No Formula defined yet
    Condition Formula

    Additional information

    A total of 733 patients with well-characterized and liver biopsy–confirmed NAFLD were included in this study. They were untreated, consecutively biopsied patients seen at the Mayo Clinic in Rochester, MN (n = 356); Newcastle, UK (n = 158); Sydney, Australia (n = 123); and Italy (n = 96) during 2000–2003. The study was approved by appropriate regulatory bodies at all centers.

    Study Population

    Total population size: 733
    Males: {{ model.numberOfMales }}
    Females: {{ model.numberOfFemales }}

    Continuous characteristics

    Name Mean SD Unit
    Age 47.7 13.2 years
    BMI 32.2 6.1 kg/m2
    Waist circumference 101.8 16.6 cm
    Waist-to-hip ratio 0.96 0.07 ratio
    ALT 87 72 U/l
    AST 60 50 U/l
    AST/ALT ratio 0.84 0.83 ratio
    Albumin 4.3 0.5 g/dl
    Billirubin 0.8 0.6 mg/dl
    AST/platelet ratio 0.94 0.9 ratio
    Platelet count 235 84 x10^9/L
    GGT 96 105 U/l
    HOMA 5.53 5.91 HOMA
    Glucose 116 50 mg/dl
    Triglycerides 211 161 mg/dl
    Total cholesterol 209 50 mg/dl
    Biopsy length 187 8.5 mm
    Portal areas 10 4.5 n

    Categorical characteristics

    Name Subset / Group Nr. of patients
    BMI Normal 47
    Overweight 243
    Obese 443
    Diabetes No 514
    Yes 219
    Hyperglycemia No 450
    Yes 283
    Hypertriglyceridemia No 295
    Yes 438
    Low HDL-cholesterol No 361
    Yes 372
    Hypertension No 513
    Yes 220
    Fibrosis stage F0 244
    F1 190
    F2 100
    F3 95
    F4 104

    Related files

    No related files available

    Supporting Publications

    No public validations available

    NAFLD score is:
    ... Points

    {{ resultSubheader }}

    {{ variable.title }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result

    NAFLD score is: Points

    {{ resultSubheader }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    Fibrosis severity scale:

    • F0 = no fibrosis
    • F1 = mild fibrosis
    • F2 = moderate fibrosis
    • F3 = severe fibrosis
    • F4 = cirrhosis

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments

    Model feedback

    No feedback yet
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString()}}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.